Lifecore Biomedical Receives Early Antitrust Clearance for Pending Acquisition

Lifecore Biomedical announced it has satisfied a key condition for its pending acquisition by Lifecore Inc. On November 4, 2026, U.S. federal regulators granted early termination of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act, removing a significant regulatory hurdle for the deal.

Key Details

• Event: Early termination of the HSR Act waiting period was granted by the Department of Justice and the Federal Trade Commission, effective November 4, 2026.
• Transaction Context: This satisfies a closing condition for the merger agreement signed on September 27, 2026, under which Lifecore Inc. will acquire Lifecore Biomedical, Inc.
• Next Steps: The completion of the merger remains subject to other closing conditions, most notably the adoption of the merger agreement by the company's stockholders.